Citius Pharmaceuticals, Inc. (CTXR)

0,7263 -0,0200 (-2,68%) Al cierre: 04:00PM EDT

Citius Pharmaceuticals, Inc.

11 Commerce Drive
First Floor
Cranford, NJ 07016
United States
908 967 6677
https://citiuspharma.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 22

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Leonard L. Mazur	Co-Founder, CEO, Chairman & Secretary	676,88k	N/A	1945
Mr. Myron Z. Holubiak	Co-Founder & Executive Vice Chairman	641,25k	N/A	1947
Dr. Myron S. Czuczman M.D.	Executive VP & Chief Medical Officer	571,38k	N/A	1960
Mr. Jaime Bartushak	Chief Business Officer, CFO & Chief Accounting Officer	527,97k	N/A	1968
Mr. Gary F. Talarico	Executive Vice President of Operations	N/A	N/A	1955
Ms. Ilanit Allen	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Dr. Alan Lader Ph.D.	Senior VP and Head of Clinical Operations & Quality Assurance	N/A	N/A	N/A
Mr. Dhananjay G. Wadekar	Senior Vice President of Business Strategy	N/A	N/A	1954
Mr. Kelly Creighton Ph.D.	Executive Vice President of Chemistry, Manufacturing & Controls	N/A	N/A	N/A
Mr. Nikolas Burlew	Executive Vice President of Quality Assurance	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Gobierno corporativo

El ISS Governance QualityScore de Citius Pharmaceuticals, Inc., a día 29 de abril de 2024, es 6. Las puntuaciones base son Auditoría: 9; Tablero: 9; Derechos de los accionistas: 1; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.